D-Pharm Ltd.October 1, 2012

D Pharm expands Chinese cooperation agreement. The agreement with Wanbang Biopharmaceuticals was extended to a new formulation of D Pharm’s treatment for ischemic stroke
D-Pharm Ltd. (TASE: DPRM) has expanded its commercialization agreement with China’s Wanbang Biopharmaceuticals Ltd. for D Pharm’s leading product, DP-b99 for the treatment of ischemic stroke. D Pharm will receive $7.65 million

D-Pharm Ltd.October 31, 2011

D-Pharm announces expected date of interim report for the DP-b99 Acute Ischemic Stroke Study, MACSI
D-Pharm Ltd., (TASE: DPRM) announced today that the interim report for the DP-b99 MACSI study is expected in February, 2012. The report will be based on the futility analysis of the data obtained from first 350 patients that complete the follow